HALBERD CORP - HALB STOCK NEWS

Halberd Corporation (OTC PINK:HALB) has contracted mdi Consultants, Inc. to help navigate the FDA’s application process for its patented technologies. With 44 years of experience and over 4,000 successful FDA submissions, mdi aims to expedite Halberd's journey toward certification. Halberd acknowledges its lack of FDA expertise and believes that mdi's guidance will substantially improve its chances of success. The company has secured exclusive rights to three patents and filed 20 related applications since its restructuring in April 2020.

Halberd Corporation (OTC PINK:HALB) has submitted its fully audited financials and Form-10 to the SEC, marking a pivotal step towards up-listing from OTC-PINK to OTCQB. This transition requires adherence to GAAP standards and timely SEC filings. CEO William Hartman emphasized this move enhances the company's credibility, attracting investor confidence. Halberd is advancing its patented technology, which targets neurological diseases, through upcoming laboratory and human clinical trials. The company is also exploring partnerships with larger firms to expedite its development timeline.

Halberd Corporation (OTC PINK:HALB) announced Dr. W. Gregg Sturrus, a member of its research team, delivered a TEDx Talk on their patented method for eliminating neurodegenerative disease proteins using lasers and nanoparticles. The presentation outlines the technology's history and its potential applications in treating various diseases. Halberd holds exclusive rights to three issued patents and has filed numerous related applications to boost shareholder value. For updates, interested parties are encouraged to subscribe for news.

Halberd Corporation (OTC PINK:HALB) reported significant advancements in Q1 2022, including the elimination of key antigens related to neurodegenerative diseases and successful tests demonstrating its proprietary Covid-19 antibody's efficacy against multiple variants. The company has strengthened its advisory team with experts in microbiology and infectious diseases. Looking ahead, Halberd aims to enhance animal testing, publish research, and explore partnerships with pharmaceutical companies. Financial audits are complete, awaiting regulatory filings. Halberd emphasizes its commitment to transparency and innovation in disease treatment.

Halberd Corporation (OTC PINK: HALB) demonstrated promising results in eradicating E. coli bacteria from cerebral spinal fluid using its patented extracorporeal methodology, achieving a 96% elimination rate in under 20 minutes, compared to 7-10 days with conventional antibiotics. This advancement could enhance recovery in patients suffering from meningitis and blood sepsis, conditions responsible for approximately 40,000 deaths annually in the U.S. Halberd’s technology aims to minimize adverse effects associated with standard treatments and prevent antibiotic resistance.

Halberd Corporation (OTC PINK:HALB) announced plans to enter the Metaverse through the creation of non-fungible tokens (NFTs) aimed at monetizing its intellectual properties, including patents and trade secrets. The company is negotiating with experts in the NFT space to identify growth opportunities and manage essential partnerships. Shareholders will independently purchase these NFTs via personalized electronic wallets, granting them tokenized rights to specific intellectual properties. This initiative aims to enhance liquidity for shareholders, providing dual sources of ownership in the company.

Halberd Corporation (OTC PINK:HALB) announced successful in vitro elimination of C-Reactive Protein (CRP) from cerebral spinal fluid using tuned laser light. This follows their success in targeting ten antigens associated with PTSD and neurodegenerative diseases. With major depression affecting 21 million Americans, Halberd aims to develop a process to lower CRP levels linked to clinical depression. CEO William Hartman highlighted ongoing laboratory experimentation, upcoming animal tests, and plans for commercialization of their findings.

Halberd Corporation (OTC PINK:HALB) advances its research by appointing Dr. Ravi Venkata Durvasula, an esteemed infectious disease expert, to its advisory team. Following the successful elimination of the Top 10 Target Antigens related to neurodegenerative diseases, Halberd aims to extend its patented extracorporeal technology to combat infectious diseases. Dr. Durvasula, affiliated with the Mayo Clinic, brings extensive expertise, having authored over 100 publications. Halberd's leadership expressed confidence in Dr. Durvasula's contributions as the company prepares for crucial animal testing.

Halberd Corporation (OTC PINK:HALB) announced the addition of Dr. Chester R. Cooper from Youngstown State University to its technical team. Dr. Cooper, a microbiology expert, has been instrumental in E. coli testing and analysis. He brings extensive experience with 47 peer-reviewed publications and has held various academic positions. His efforts will focus on advancing Halberd's research on neurodegenerative diseases and developing methods for eradicating bacterial infections using lasers and radio frequency.